COIOSDeep risk insights through multi-disciplinary research across the globe
a city street filled with lots of traffic and tall buildings
Item new Preprint · not peer-reviewed Added

Varenicline users had about half the dementia rate of nicotine-replacement users

Among 1,758 matched pairs aged 50 and over in the All of Us cohort, varenicline users had about half the rate of dementia of those using nicotine replacement (HR 0.52).

The authors matched 1,758 varenicline initiators to 1,758 nicotine replacement users aged 50 or over in All of Us, covering 2006 to 2023. Dementia incidence was lower among varenicline users (HR 0.52, 95% CI 0.35 to 0.75). Dementia or death combined gave a hazard ratio of 0.66, and varenicline was picked out by a medication-wide screen rather than a prior hypothesis.

Why it is interesting: An existing smoking cessation drug tracks with lower dementia incidence among older adults with a smoking history.

Source
medRxiv, 20 September 2026
Paper
Varenicline as a Repurposable Drug Candidate for ADRD Prevention
Authors
Ma P, Zhou J, Cheng Y, McGeary JE, Taveira TH, Ahmed A et al.
DOI
10.64898/2026.09.17.26363232
Type
Preprint
Design
Propensity-matched active-comparator cohort in All of Us, 9,584 initiators aged 50+ (1,758 matched pairs), 2006-2023
Verdict
New finding
Driver
Dementia
Driver
Smoking and vaping
Attention
1 citation (Crossref) · as of 2026-11-15
Abstract — the authors' own words, CC BY

Objective

Effective strategies to prevent Alzheimer’s disease and related dementias (ADRD) are limited. Implementing our Medication-Wide Association Study (MWAS+), we highlighted varenicline as a candidate. This study evaluated the association between varenicline use and risk of ADRD relative to nicotine replacement therapy (NRT). Methods

Using the All of Us Research Database, we identified adults aged 50 years or older with available lifestyle survey responses regarding tobacco use history who initiated smoking cessation therapy with either varenicline or NRT between 2006 and 2023. We limited our cohort to incident monotherapy users and designated the index date as the first prescription. Individuals with baseline ADRD or no follow-up were excluded. Baseline characteristics included demographics, comorbidities, BMI, and prior medication exposures. Outcomes were incident ADRD and a composite outcome of ADRD or death. Findings

The cohort consisted of 9,584 individuals (1,801 varenicline users and 7,783 NRT users). After propensity score matching, there were 1,758 individuals in each group with balanced baseline characteristics. Varenicline use was associated with a reduced risk of ADRD (HR 0.516, 95% CI: 0.353–0.754) and the composite outcome ADRD or death (HR 0.657, 95% CI: 0.501–0.861). Kaplan–Meier curves also demonstrated varenicline’s sustained benefits through the study period. Implications

Varenicline use is associated with a lower risk of ADRD among older adults receiving smoking cessation therapy. Further investigation of varenicline as a potential strategy for ADRD prevention is warranted. These findings underscored the value of explainable AI-guided approaches to drug repurposing. Highlight

Artificial Intelligence (AI) Medication-Wide Association Study (MWAS+) identified varenicline as candidate for ADRD prevention. Varenicline linked to lower ADRD risk vs NRT in propensity score matched cohort. Consistent results for ADRD and composite outcome ADRD or death.

Other drivers in Health today